EDAP (EDAP) to Distribute Lumenis Urological Lasers in France

LYON, France, June 24, 2010 (GLOBE NEWSWIRE) — EDAP TMS SA (Nasdaq:EDAP – News), the global leader in therapeutic ultrasound, announced today that it has signed an exclusive agreement with Lumenis, GmbH, to distribute Lumenis urological Holmium/Nd:YAG lasers in France, starting June 2010.

This exclusive distribution agreement will allow EDAP to broaden its products portfolio by offering urologists a new and high-end therapeutic option to their existing tools. Lumenis lasers enable precise minimally invasive treatment for a wide variety of urologic conditions such as benign prostatic hyperplasia (BPH) and bladder, urethral and kidney stones. With its strong knowledge of the French urology market and its close relationships with French urologists, EDAP is well positioned to strengthen its leadership in stone management and urology with the addition of Lumenis’ high-end technology lasers.

Marc Oczachowski, CEO, commented, “I am very enthusiastic about adding Lumenis lasers, recognized as top ranked urology lasers, to our product offering in France. For years, EDAP has proven its leadership and track record in selling urological medical devices in France. In addition to representing a new revenue opportunity, the distribution of Lumenis’ lasers in France will reinforce EDAP’s presence in the urological field by further positioning us as one of the major players offering a wide range of minimally-invasive technologies to patients with urological conditions.”

Lloyd Diamond, President EMEA, from Lumenis, added, “We are pleased to enter into this distribution agreement with EDAP. The French urology market is important to Lumenis and we now have the best partner to develop and support it. The combination of EDAP and Lumenis products provides a comprehensive solution to many of the urologists’ stone and prostate needs.”

About EDAP TMS SA

EDAP TMS SA develops and markets Ablatherm, the most advanced and clinically proven choice for high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Approved in Europe as a treatment for prostate cancer, Ablatherm-HIFU (High Intensity Focused Ultrasound) is currently undergoing evaluation in a multicenter U.S. Phase II/III clinical trial under an Investigational Device Exemption granted by the FDA. The Company also is developing this technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and commercializes medical equipment for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the company, please visit http://www.edap-tms.com, http://www.hifu-planet.com.

About Lumenis

Lumenis, one of the world’s largest medical laser companies, is a global developer, manufacturer and distributor of laser and light-based devices for surgical, ophthalmic and aesthetic applications, with more than 800 employees worldwide. Lumenis has nearly 250 patents, over 75 FDA clearances, an installed base of over 80,000 systems and presence in over 100 countries. Lumenis endeavors to bring the finest state of the art technology products to the market, fulfilling the highest standards of excellence, quality and reliability, delivering premium value and service to its customers. The name Lumenis is derived from the Latin words meaning “Light of Life” highlighting the light, which is the basis of our technologies used to enhance life. For more information about Lumenis and its products, please go to: http://www.lumenis.com.